Biotech in Focus

OREX, HALO, BMRN, BAX,

“Much of the research coverage on Wall St. from the bulge bracket firms is concentrated on the most liquid, best known names from the S&P 500. These names are recognizable to investors and are reasonably easy to cover by their analysts from a data standpoint. In addition to Wall St. research, we make an all out effort to find other stock coverage for our readers that can prove valuable. One area that does not get the coverage it should is biotech and biopharma. The stocks in those sectors offer investors high risk, and often high reward.

PropThink is a specialty research firm that focuses its coverage on the biotech and biopharma arena. We went through their research, looking for not only their best investment ideas, but stocks that had a solid thesis. It is important for investors to remember that many of these stocks are dependent on some form of U.S. Food and Drug Administration (FDA) approval, and the delay or lack of that approval can be devastating to the stock price.

The following are some of the best investment ideas from PropThink…”

Full article